Hepatitis B
EASL International Liver Congress Starts This Week in Barcelona
- Details
- Category: HBV Treatment
- Published on Tuesday, 17 April 2012 00:00
- Written by Liz Highleyman
The 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012) takes place this week, April 18-22, in Barcelona. HIVandHepatitis.com will be on site to provide breaking news and analysis.
Androgens Promote Hepatitis B Virus Replication, Helping Explain Sex Differences
- Details
- Category: HBV Basic Science
- Published on Tuesday, 21 February 2012 00:00
- Written by Liz Highleyman
The hepatitis B virus (HBV) carries receptors for androgens -- male hormones such as testosterone -- which may help explain why men are more likely than women to develop chronic hepatitis B and experience more aggressive liver disease, according to study findings reported in the February 2012 Journal of Virology.
MicroRNA Blood Test May Help Diagnose Early Liver Cancer in People with Hepatitis B
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 03 January 2012 00:00
- Written by Liz Highleyman
A set of 7 microRNAs in blood plasma accurately diagnosed hepatocellular carcinoma (HCC) and could distinguish between liver cancer and cirrhosis among people with chronic hepatitis B, according to study findings reported in the November 21, 2011, advance online edition of the Journal of Clinical Oncology.
Statins May Reduce Liver Cancer Risk among People with Hepatitis B
- Details
- Category: Liver Cancer/HCC
- Published on Friday, 10 February 2012 00:00
- Written by Liz Highleyman
Statins, a class of drugs used to manage elevated blood cholesterol, may also play a role in fighting hepatocellular carcinoma (HCC) -- a form of primary liver cancer -- among people with chronic hepatitis B, according to a report in the January 23, 2012, advance online edition of the Journal of Clinical Oncology.
Do Not Use Telbivudine (Tyzeka) with Pegasys for Hepatitis B, FDA Warns
- Details
- Category: Drug Advisories & Warnings
- Published on Tuesday, 27 December 2011 00:00
- Written by Press Release
The U.S. Food and Drug Administration (FDA) last week announced revisions to the product label for the nucleoside analog telbivudine (Tyzeka), indicating that it should not be used with pegyalted interferon alfa-2a (brand name Pegasys) for the treatment of hepatitis B because the combination can cause peripheral neuropathy, or nerve damage.
High HBV Viral Load Linked to Greater Risk of Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 17 January 2012 00:00
- Written by Liz Highleyman
Having a high blood level of hepatitis B virus (HBV) DNA increases the likelihood of developing hepatocellular carcinoma (HCC), a form of primary liver cancer, according to a study described in the January 13, 2012, Journal of Virology.
AASLD: Natural History of Hepatitis B Infection and Role of HBV Genotype
- Details
- Category: Hepatitis B
- Published on Tuesday, 20 December 2011 00:00
- Written by Liz Highleyman
People with hepatitis B "e" antigen (HBeAg) positive and negative disease have different levels of hepatitis B surface antigen (HBsAg), variable extent of liver fibrosis, and different distribution of HBV genotypes, according to a study presented at the American Association for the Study of Liver Disease (AASLD) Liver Meeting last month in San Francisco.
Hepatitis B and C Are Major Causes of Liver Cancer in U.S.
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 10 January 2012 00:00
- Written by Press Release
Chronic hepatitis C infection has replaced alcohol-related cirrhosis as a major cause of hepatocellular carcinoma (HCC, a form of primary liver cancer) in the U.S., according to a study by researchers at the Mayo Clinic in Rochester, MN. A related analysis found that among immigrants from Somalia, hepatitis B and C were both significant causes of liver cancer.
More U.S. Immigrants May Have Hepatitis B than Previously Estimated
- Details
- Category: HBV Epidemiology & Mortality
- Published on Tuesday, 06 December 2011 00:00
- Written by Liz Highleyman
The number of foreign-born individuals with chronic hepatitis B virus (HBV) infection in the U.S. may be considerably higher than earlier estimates suggest, according to a study described in the November 22, 2011, advance online edition of Hepatology.
More Articles...
- AASLD: Upping Entecavir Dose Does Not Improve Hepatitis B Treatment Response
- AASLD: Good Response to Entecavir Reduces Risk of Hepatitis B Liver Disease Progression
- AASLD: Long-term Tenofovir for HIV/HBV Coinfection
- AASLD: Engineered Poxvirus Shows Promise for Treating Advanced Liver Cancer
- AASLD: Long-Term Tenofovir for Chronic Hepatitis B Reduces Liver Inflammation and Cirrhosis
Web Design and Development by